Paper Details

  1. Home
  2. Paper Details

Suprachoroidal injection of triamcinolone acetonide plus intravitreal bevacizumab in diabetic macular edema: a randomized pilot trial.

Author: FazelFarhad, FazelMohammadreza, FeiziAwat, MalekahmadiMohammad, OliyaBehrooz, TavakoliMehdi

Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This study investigated the efficacy of injecting suprachoroidal triamcinolone acetonide (SCTA) plus intravitreal bevacizumab (IVB) in patients with center-involving diabetic macular edema (CI-DME). The combination therapy showed significant improvements in best-corrected visual acuity (BCVA) and central subfield thickness (CST) compared to monotherapy with IVB alone. The combination therapy demonstrated additive effects with no short-term side effects and appears to be a promising treatment option for patients with CI-DME.
Paper Details　
Original Abstract of the Article :
BACKGROUND: To investigate the efficacy of injecting suprachoroidal triamcinolone acetonide (SCTA) plus intravitreal bevacizumab (IVB) into patients with center-involving diabetic macular edema (CI-DME). METHODS: In this phase 2/3 randomized controlled pilot trial, sixty-six eyes with CI-DME and be...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9881520/

データ提供：米国国立医学図書館（NLM）

A New Approach to Diabetic Macular Edema: A Combination Therapy

This pilot trial investigates the efficacy of combining suprachoroidal triamcinolone acetonide (SCTA) injection with intravitreal bevacizumab (IVB) in treating diabetic macular edema (DME). The study aimed to determine if this combination therapy could provide superior results compared to IVB monotherapy.

A Promising Oasis in the Desert of Diabetic Macular Edema

The study found that the combination therapy significantly improved both visual acuity and retinal thickness compared to IVB monotherapy. The results suggest that SCTA may offer an additive effect to anti-vascular endothelial growth factors, providing a potentially more effective treatment option for patients with DME.

A Glimpse into the Future of DME Management

This research offers a promising avenue for managing DME, a condition that can significantly affect vision. The combination therapy approach could potentially provide more effective and durable treatment outcomes, improving the quality of life for patients with DME.

Dr.Camel's Conclusion

The desert of DME treatment is vast and complex, but this study offers a potential oasis of hope. The combination therapy approach could bring us closer to more effective and sustainable treatment solutions for this challenging condition.

Date :
  1. Date Completed 2023-01-31
  2. Date Revised 2023-02-02
Further Info :

Pubmed ID

36707790

DOI: Digital Object Identifier

PMC9881520

Related Literature

Article Analysis
・Side Effects of triamcinolone
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.